Select examples from our investment portfolio include:
Besivance, Ophthalmic Antibiotic
$15 million – Royalty Acquisition
Tissue Regeneration Therapeutics
$3.25 million – Royalty Acquisition
B&D Dental
$6 million – Revenue Interest Debt Financing
-
Private Biotechnology Company
$3 million – Syndicated Royalty Bond
Cambia, Migraine Therapeutic
$4.5 million – Royalty Acquisition
ABT Molecular
$10 million – Synthetic Royalty Financing
DxTerity Diagnostics
$7.5 million – Revenue Interest Debt Financing
Acerus Pharmaceuticals
$11 million – Revenue Interest Debt Financing
Soluble Systems
$12 million – Revenue Interest Debt Financing
Cambia, Migraine Therapeutic
$5.0 million – Royalty Acquisition
Thermedx
$3.5 million – Synthetic Royalty Financing
Tenex Health
$9 million – Revenue Interest Debt Financing
Keystone Dental
$20 million – Revenue Interest Debt Financing
Forfivo XL
$6 million – Royalty Acquisition
NARCAN Nasal Spray
$17.5 million – Royalty Acquisition
Imprimis Pharmaceuticals, Inc.
$16 million – Revenue Interest Debt Financing
CeloNova BioSciences, Inc.
Debt Financing
Veru Inc.
$12 million – Synthetic Royalty Financing
Beleodaq
$7.5 million – Royalty Acquisition
Epica International
$14 million – Revenue Interest Debt Financing
Cheetah Medical
$14 million – Revenue Interest Debt Financing
Previous Investments
InnoPran XL, Approved Beta Blocker for Hypertension
$13 million – Acquisition & Sublicensing
Nautilus Neurosciences
$22.5 million – Revenue Interest Debt Financing
Parnell Pharmaceuticals
$25 million – Synthetic Royalty Financing
PDI, Inc.
$20 million – Structured Debt & Synthetic Royalty Financing
Response Genetics, Inc.
$12 million – Revenue Interest Debt Financing
Tribute Pharmaceuticals
$17 million – Revenue Interest Debt Financing
SynCardia Systems
$10 million – Structured Debt & Synthetic Royalty Financing
Galil Medical
$12.5 million – Revenue Interest Debt Financing
Nanosphere
$30 million – Revenue Interest Debt Financing
Hooper Holmes
$5.0 million – Revenue Interest Debt Financing
OraMetrix, Inc.
$8.5 million – Revenue Interest Debt Financing
Parnell Pharmaceuticals
$20 million – Revenue Interest Debt Financing
Hooper Holmes
$8.5 million – Revenue Interest & Seasonal Facility Debt Financing
EyePoint Pharmaceuticals
$20 million – Revenue Interest Debt Financing